Lantern Pharma to Showcase withZeta.ai Platform in Investor Briefing

Lantern Pharma announced it will host an investor, analyst and shareholder briefing on April 9, 2026, featuring a live demonstration of withZeta.ai, described as the first multi-agentic AI co-scientist for rare cancer drug discovery, development and clinical trial design. The webcast will highlight the platform’s capabilities, commercial architecture, competitive positioning and revenue strategy, alongside an overview of the rare cancer market opportunity and Lantern’s growth roadmap, with participation from CEO Panna Sharma and Chief Scientific Officer Kishor Bhatia.

The company’s proprietary AI and machine learning platform, RADR(R), leverages over 200 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development and generate oncology medicines at dramatically reduced costs and accelerated timelines. On average, Lantern Pharma’s newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2–3 years and at approximately $1.0–2.5 million per program, representing a significant reduction compared to traditional pharmaceutical development approaches.

Lantern Pharma’s AI-driven pipeline of innovative product candidates is estimated to have a combined annual market potential of over $15 billion USD, with lead development programs including a Phase 2 clinical program and multiple planned Phase 1b/2a clinical trials. The company has also established a wholly-owned subsidiary, Starlight Therapeutics, to focus exclusively on the clinical execution of promising therapies for CNS and brain cancers, demonstrating a strategic approach to addressing challenging oncology indications.

The upcoming investor briefing matters because it represents a public demonstration of a platform that could potentially transform how rare cancer treatments are discovered and developed. The withZeta.ai platform’s positioning as a multi-agentic AI co-scientist suggests a sophisticated approach to artificial intelligence in drug discovery, where multiple AI agents work collaboratively on complex scientific problems. This development is important because rare cancers often receive less research attention due to smaller patient populations, yet they collectively represent a significant unmet medical need. The platform’s focus on accelerating timelines and reducing costs could make drug development for rare cancers more economically viable, potentially bringing more treatments to market for patients with limited options.

The demonstration will provide insight into how artificial intelligence can address specific challenges in oncology drug development, including clinical trial design for rare cancers where patient recruitment can be particularly difficult. The company’s approach of leveraging massive datasets and advanced algorithms represents a growing trend in pharmaceutical research where computational methods are supplementing traditional laboratory work. For investors and analysts, the briefing offers an opportunity to assess the commercial viability of AI-driven drug discovery platforms and their potential to generate sustainable revenue streams in the competitive pharmaceutical landscape.